Analyst Ratings For Global Blood Therapeutics (NASDAQ:GBT)
Today, William Blair reiterated its Buy rating on Global Blood Therapeutics (NASDAQ:GBT).
Some recent analyst ratings include
- 2/28/2018-William Blair Reiterated Rating of Buy.
- 2/13/2018-Janney Montgomery Scott initiated coverage with a Buy rating.
- 12/15/2017-Wedbush Reiterated Rating of Outperform.
Recent Insider Trading Activity For Global Blood Therapeutics (NASDAQ:GBT)
Global Blood Therapeutics (NASDAQ:GBT) has insider ownership of 5.30% and institutional ownership of 87.81%.
- On 2/16/2018 Jung Choi, Insider, sold 3,000 with an average share price of $62.95 per share and the total transaction amounting to $188,850.00.
- On 2/1/2018 Peter Radovich, Insider, sold 812 with an average share price of $57.30 per share and the total transaction amounting to $46,527.60.
- On 1/23/2018 Peter Radovich, Insider, sold 30,000 with an average share price of $60.00 per share and the total transaction amounting to $1,800,000.00.
- On 1/17/2018 Jung Choi, Insider, sold 3,000 with an average share price of $52.85 per share and the total transaction amounting to $158,550.00.
- On 1/10/2018 Peter Radovich, Insider, sold 15,000 with an average share price of $50.00 per share and the total transaction amounting to $750,000.00.
- On 12/19/2017 Perceptive Advisors Llc, Major Shareholder, bought 175,000 with an average share price of $38.00 per share and the total transaction amounting to $6,650,000.00.
- On 12/18/2017 Jung Choi, Insider, sold 3,000 with an average share price of $36.55 per share and the total transaction amounting to $109,650.00.
Recent Trading Activity for Global Blood Therapeutics (NASDAQ:GBT)
Shares of Global Blood Therapeutics closed the previous trading session at 60.10 down -1.35 2.20% with 61.95000076293945 shares trading hands.